

dry basis, being at least 0.005 wt%.

Sub-B1  
2. (Amended) The method of claim 1, wherein the blend ratio of [A drug against ultraviolet light-induced skin immunosuppression which characteristically contains] glutathione in the liniment, on a dry basis, is 0.005-20.0 wt%.

G2  
3. (Amended) The method of claim 1, wherein the blend ratio of glutathione in the [An immunopotentiating endermic] liniment, on a dry basis, is 0.01-10.0 wt% [for preventing ultraviolet light-induced skin immunosuppression].

Sub E1  
4. (Amended) The method of claim 1, wherein said [An endermic] liniment [against ultraviolet light-induced skin immunosuppression which characteristically contains glutathione] is in a form of a member selected from the group consisting of ointment, cream, emulsion, lotion, facial pack and bath additive.

Kindly add new claims 15-18 as follows:

Sub-B2  
15. A method for controlling immunosuppression due to contact of the skin by ultraviolet light, comprising applying to the skin an immunopotentiator composition comprising glutathione, the blend ratio of glutathione in the immunopotentiator composition, on a dry basis, being 0.005-20.0 wt%.

G3  
16. The method of claim 15, wherein the blend ratio of glutathione in the ~~immunopotentiator~~ composition, on a dry basis, is 0.05-10.0 wt%.

B  
17. The method of claim 15, wherein the ~~immunopotentiator~~